1. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F (1969) Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 3(5669):503–506
2. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G (1970) Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30(10):2572–2582
3. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592
4. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13(6):819–829
5. Steinherz L, Steinherz P (1991) Delayed cardiac toxicity from anthracycline therapy. Pediatrician 18(1):49–52